Viemed Healthcare, Inc. announced on May 6 that it entered into an agreement to acquire Lehan Drugs, Inc. Lehan is being acquired for a base purchase price of $26 million, subject to customary net working capital adjustments and an estimated $2.2 million of contingent payments.
Lehan Drugs is a provider of durable medical equipment with six locations: five in Illinois and one in Wisconsin. Its products include sleep apnea machines, mobility aides and breast pumps. According to the original deal press release from May 6, 2025, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million in 2024.
Viemed Healthcare is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology.
This acquisition, expected to close in the third quarter of 2025, aims to diversify Viemed’s product offerings into maternal health and expand its market presence. Lehan’s Medical Equipment owners Jim and Jon Lehan and the more than 90 employees at the company will join Viemed upon the completion of the transaction. Viemed expects to fund the acquisition through a combination of cash on hand and borrowings from its existing credit facilities.
According to data captured in the LevinPro HC database, this transaction marks the 39th Home Health & Hospice transaction of 2025, and the third in the durable medical equipment/respiratory home care specialty.
